MSN’s Novadoz Makes Multiple US Launches
Company Commences Shipping Of Albendazole, Droxidopa, Deferasirox And Pregabalin
India’s MSN Labs has kicked off the year by launching four recently-approved generics in the US through affiliate Novadoz, including albendazole, droxidopa, deferasirox and pregabalin. The company says it is preparing a “deep pipeline” of launches for the next 10 years.
You may also be interested in...
Denmark’s Lundbeck is aiming to build up use of its latest neurological, the long-acting migraine preventative, Vyepti, now that US healthcare is emerging from COVID-19-related restrictions, but is facing headwinds from loss of exclusivity on Northera.
Pfizer reported double-digit growth in its biosimilars and sterile injectables segments, as the company indicated that it would take a more “opportunistic” approach to its biosimilars business in future. The company has also revised its overall 2021 financial guidance as it expects better numbers on the back of its COVID-19 vaccine business.
BioXpress Therapeutics and Abzena, two service providers with expertise in biosimilar development, have partnered to support biosimilar development for third party customers. The companies plan to offer a “flexible and innovative approach from small scale biosimilar development through to large scale manufacturing.”